GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT06411249
- Locations
- 🇪🇸
GSK Investigational Site, Villajoyosa, Spain
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT06405230
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1459
- Registration Number
- NCT06389487
- Locations
- 🇿🇦
GSK Investigational Site, Reiger Park, South Africa
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
Phase 1
Recruiting
- Conditions
- Influenza, Human
- Interventions
- Biological: Flu Pandemic mRNA_Dose level 1Biological: Flu Pandemic mRNA_Dose level 2Biological: Flu Pandemic mRNA_ Dose level 3.Biological: Flu Pandemic mRNA_ Dose level 4Biological: Flu Pandemic mRNA_Dose level 5Drug: PlaceboBiological: Flu Pandemic mRNA_Dose level 6
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 996
- Registration Number
- NCT06382311
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
Phase 3
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSVPreF3 OA investigational vaccineBiological: COVID-19 mRNA vaccine
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 842
- Registration Number
- NCT06374394
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
Phase 4
Active, not recruiting
- Conditions
- Asthma
- Interventions
- Drug: Inhaled corticosteroids/long-acting beta-2 agonists
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1358
- Registration Number
- NCT06372496
- Locations
- 🇨🇳
GSK Investigational Site, Taichung, Taiwan
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: EE/LNGDrug: GSK3036656 Dose Level 1Drug: GSK3036656 Dose Level 2
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT06354257
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants
Phase 3
Completed
- Conditions
- Gastroenteritis
- Interventions
- Combination Product: HRV PCV-freeCombination Product: IPV
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 400
- Registration Number
- NCT06331156
- Locations
- 🇨🇳
GSK Investigational Site, Yuechi-Guang'an, China
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT06317285
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Phase 2
Recruiting
- Conditions
- Carcinoma
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT06317311
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath